Get the Stockscreener App
1.98
64.98%
0.75
Geovax Labs Inc stock is traded at $1.98, with a volume of 177.61M.
It is up +64.98% in the last 24 hours and up +63.65% over the past month.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
See More
Previous Close:
$1.23
Open:
$3.03
24h Volume:
177.61M
Relative Volume:
61.23
Market Cap:
$7.00M
Revenue:
$2.49M
Net Income/Loss:
$-21.46M
P/E Ratio:
-0.1014
EPS:
-19.526
Net Cash Flow:
$-21.50M
1W Performance:
+37.11%
1M Performance:
+63.65%
6M Performance:
-80.10%
1Y Performance:
-91.76%
1-Day Range:
$1.94
$4.39
1-Week Range:
$1.20
$4.39
52-Week Range:
$0.9631
$34.75
Geovax Labs Inc Stock (GOVX) Company Profile
Name
Geovax Labs Inc
Sector
Industry
Phone
678-384-7220
Address
1955 LAKE PARK DRIVE, SMYRNA
Compare GOVX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOVX
Geovax Labs Inc
|
2.015 | 4.27M | 2.49M | -21.46M | -21.50M | -19.53 |
VRTX
Vertex Pharmaceuticals Inc
|
436.69 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
628.21 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
785.34 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.35 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
141.70 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Downgrade | D. Boral Capital | Buy → Hold |
| Apr-15-25 | Reiterated | Alliance Global Partners | Buy |
| Apr-15-25 | Reiterated | D. Boral Capital | Buy |
| Nov-11-24 | Initiated | Alliance Global Partners | Buy |
| Jul-16-24 | Initiated | ROTH MKM | Buy |
| Nov-19-20 | Initiated | Maxim Group | Buy |
View All
Geovax Labs Inc Stock (GOVX) Latest News
GeoVax Labs (GOVX) jumps 178% as traders refocus on mpox vaccine thesis after recent Q1 update - Quiver Quantitative
GOVX Stock Rockets On Heavy Volume As Traders Pile In - StocksToTrade
GeoVax Jumps Pre-market as Traders Eye Biotech’s Mpox Vaccine Push - TechStock²
All you need to know about GeoVax Labs (GOVX) rating upgrade to buy - MSN
Roth MKM Maintains GeoVax Labs(GOVX.US) With Buy Rating, Maintains Target Price $10 - Moomoo
All You Need to Know About GeoVax Labs (GOVX) Rating Upgrade to Buy - Yahoo Finance
Armistice Capital reports 9.99% stake in GEOVAX Labs (GOVX) via Master Fund - Stock Titan
GOVX Stock Chart | GEOVAX LABS INC (NASDAQ:GOVX) - ChartMill
GeoVax Advances GEO-MVA Phase 3 Trial as First Quarter 2026 Loss Narrows - citybuzz -
GeoVax Reports Q1 2026 Net Loss $5.3M, Cash $1.3M, Advances GEO-MVA Phase 3 Plans - TradingView
GeoVax (GOVX) Q1 2026 loss steady as cash falls and GEO-MVA advances - Stock Titan
GeoVax Labs | 10-Q: Q1 2026 Earnings Report - Moomoo
GeoVax Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
GeoVax (GOVX) Q1 2026 shows flat loss but cash only into June - Stock Titan
GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation Plans - Yahoo! Finance Canada
GeoVax Highlights Gedeptin’s Potential in Combination Immunotherapy for Cold Tumors - citybuzz -
GeoVax Labs (NASDAQ: GOVX) holders report 233,337 shares equal to 9.99% stake - Stock Titan
GeoVax Highlights Emerging Role of Gedeptin(R) in Combination Immunotherapy Strategies Targeting Immunologically Cold Tumors - Yahoo Finance
GeoVax Labs Announces Warrant Inducement and Financing Move - The Globe and Mail
GeoVax Labs (NASDAQ: GOVX) asks shareholders to OK warrant exercises totaling millions - Stock Titan
GeoVax Labs (GOVX) surges 6.7% after Q4 2025 earnings crush estimates by nearly 100%Crowd Breakout Signals - newser.com
GOVX Technical Analysis | Trend, Signals & Chart Patterns | GEOVAX LABS INC (NASDAQ:GOVX) - ChartMill
GeoVax (Nasdaq: GOVX) raises $595K, adds new warrant package - Stock Titan
GeoVax Announces a Warrant Inducement Transaction - The Globe and Mail
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway - Yahoo Finance
$GeoVax Labs (GOVX.US)$ Thanks for the spike last week! I be back... - Moomoo
GOVX Forecast, Price Target & Analyst Ratings | GEOVAX LABS INC (NASDAQ:GOVX) - ChartMill
GeoVax Advances Gedeptin Toward Phase 2 Trials and Seeks Partnership Opportunities - citybuzz -
GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership Opportunities - Yahoo Finance
GeoVax Labs Inc expected to post a loss of $4.42 a shareEarnings Preview - TradingView
GeoVax Positions Gedeptin as Immune-Sensitizing Platform Amid Rising Investment in In Vivo Cancer Therapies - citybuzz -
Large warrant share approvals headline GeoVax (GOVX) 2026 proxy and annual meeting - Stock Titan
GeoVax Highlights Gedeptin(R) as a Potential Immune-Sensitizing Platform Amid Rising Industry Investment in In Vivo Cancer Therapies - Yahoo Finance
[EFFECT] GeoVax Labs, Inc. SEC Filing - Stock Titan
GOVX SEC FilingsGeovax Labs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
GeoVax Labs (NASDAQ: GOVX) adds auditor consent in S-1 amendment - Stock Titan
[POS EX] GeoVax Labs, Inc. SEC Filing - Stock Titan
GeoVax Labs (NASDAQ: GOVX) adds Wipfli auditor consent in S-1 amendment - Stock Titan
GeoVax Labs (NASDAQ: GOVX) seeks votes to approve Feb/March 2026 warrant exercises - Stock Titan
GOVX Maintained by D. Boral Capital -- Price Target Steady at $1 - GuruFocus
GeoVax Labs (GOVX) Stock vs Peers (Edges Lower) 2026-04-16Scalping - Xã Thanh Hà
GeoVax Labs, Inc. Files Form 8-K with Nasdaq: Company Details, Financial Highlights, and Key Disclosures - Minichart
GeoVax Labs, Inc. 2024 Annual Report: Clinical Pipeline, Business Overview, Risks, and Intellectual Property Strategies - Minichart
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update - National Today
GeoVax Labs (NASDAQ: GOVX) resale of 2.27M warrant shares, no issuer proceeds - Stock Titan
GeoVax Labs (NASDAQ: GOVX) investors face going concern, dilution risks - Stock Titan
GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial Amid Global Supply Concerns - citybuzz -
Form 8-KCurrent report - ADVFN
GeoVax Labs Inc reports results for the quarter ended December 31Earnings Summary - TradingView
GeoVax Labs (NASDAQ: GOVX) details vaccine pipeline and flags going concern risk - Stock Titan
GeoVax Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Geovax Labs Inc Stock (GOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):